T1	control 551 558	placebo
T2	intervention 562 571	tamoxifen
T5	eligibility 1073 1204	Participants enrolled at least three years before trial unblinding and without medically indicated discontinuation before 12 months
T6	total-participants 1249 1255	10 576
T7	outcome 1349 1364	three-month MCS
T8	outcome 1450 1482	three-month gynecologic symptoms
T9	outcome 1550 1577	baseline vasomotor symptoms
T10	outcome 1655 1682	three-month sexual symptoms
T11	outcome 1796 1822	three-month other symptoms
T12	outcome 1858 1861	PCS
